Eli Lilly and Company

The University of North Carolina at Chapel Hill

Hector Aldaz

Stephen John Demarest

Brian Arthur Kuhlman

Shane Krummen Atwell

Karen Jean Froning

Andrew Philip Leaver-Fay

Ying Tang

Jirong Lu

Ling Liu

Barrett Allan

Pia Pauliina Yachi

Sheng-Hung Rainbow Tschang

The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (C3/C3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

IgG bispecific antibodies and processes for preparation

Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.

Multifunctional antibodies binding to EGFR and MET

Growing community of inventors

San Marcos, CA, United States of America

Hector Aldaz